Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M, Fujii M
Department of Medicine, National Shikoku Cancer Center Hospital, Matsuyama, Japan.
Lung Cancer. 1996 Aug;15(1):67-77. doi: 10.1016/0169-5002(96)00571-5.
In an attempt to determine the prognostic significance of pretreatment factors for patients with advanced non-small cell lung cancer (NSCLC), 24 pretreatment clinical variables were analyzed for 185 patients with NSCLC who underwent chemotherapy and/or radiotherapy between 1985 and 1994. Following univariate analysis, we applied two multivariate statistical techniques. In a Cox regression mode, independently significant factors influencing patient survival included performance status (PS), disease stage, hemoglobin level, and serum calcium level. Recursive partitioning and amalgamation (RPA) resulted in three distinct prognostic subgroups based on PS, stage, weight loss, and hemoglobin level. The best survival was observed for patients with a good PS and Stage III disease who had a hemoglobin level > 11 g/dl. The worst survival was observed for patients with a poor PS and presence of weight loss irrespective of stage. All other patients had an intermediate prognosis. Median survival times were 95.1 weeks, 17.1 weeks and 39.3 weeks, respectively (P < 0.00005). The results of our analyses show that three important prognostic subgroups could readily be discerned using RPA.
为了确定晚期非小细胞肺癌(NSCLC)患者预处理因素的预后意义,我们分析了1985年至1994年间接受化疗和/或放疗的185例NSCLC患者的24项预处理临床变量。单因素分析后,我们应用了两种多变量统计技术。在Cox回归模型中,影响患者生存的独立显著因素包括体能状态(PS)、疾病分期、血红蛋白水平和血清钙水平。递归分割合并法(RPA)根据PS、分期、体重减轻和血红蛋白水平得出了三个不同的预后亚组。PS良好且为Ⅲ期疾病、血红蛋白水平>11 g/dl的患者生存率最佳。PS差且存在体重减轻的患者,无论分期如何,生存率最差。所有其他患者预后中等。中位生存时间分别为95.1周、17.1周和39.3周(P<0.00005)。我们的分析结果表明,使用RPA可以很容易地识别出三个重要的预后亚组。